Kroll Ontrack Integrates Relativity into Its Ediscovery Offering in Europe
Kroll Ontrack, the leading provider of ediscovery and data recovery products and services, today announced it is adding kCura's Relativity to its ediscovery offering in Europe. As a Relativity Premium Hosting partner, Kroll Ontrack is now giving law firms and companies flexibility in their choice of document review tools, based on the needs of their projects.
Kroll Ontrack has successfully offered Relativity in the US since 2014 and has integrated proprietary, award-winning technology enhancements – including cost-saving nearline technology – into its Relativity offering to give clients greater control of their data and costs. This enhanced offering of Relativity is now available in the UK and will be deployed in other European countries too.
Tim Phillips, Managing Director of Kroll Ontrack International Legal Technologies said: “Kroll Ontrack is making it easier for both law firms and companies to choose a leading review tool best suited to their needs, either ediscovery.com Review or Relativity, based on workflow requirements, data analytics, user preferences and other features. Regardless of their choice, clients are supported by Kroll Ontrack’s global network of consulting experts who help clients leverage the most advanced technology features to gain better control over their overall data volumes and ediscovery spend.”
John Grancarich, vice president of product management, Kroll Ontrack said: “Each and every ediscovery project is unique, with different parameters and deadlines, requiring different technology functionality. The addition of Relativity to our ediscovery offering means our team is equipped with a flexible toolkit and the expertise to recommend the best approach to solve every customer challenge.”
Kroll Ontrack received the 2015 Relativity Innovation Award for Best Service Provider Solution for its integration of proprietary “nearline” technology – originally built to reduce data volumes and costs in ediscovery.com Review – into its offering of Relativity. Nearline technology empowers users to easily identify and set aside (or nearline) non-critical data on demand, and retrieve nearline data in a similar, on-demand manner, without reprocessing and with work product intact. As nearline storage is 50 percent less costly than active storage, organisations can significantly reduce data volumes and costs associated with ediscovery, while providing more efficient access to critical documents.
Tim Phillips continues: “Organisations are seeking ways to leverage technology to reduce the costs associated with ediscovery and reduce time spent reviewing documents. Our nearline technology addresses both. Over the last 12 months, nearly 100 clients have taken advantage of cost-saving nearline technology in ediscovery.com Review.”
Kroll Ontrack’s integration of this proprietary technology into Relativity directly addresses the market demand for innovative, cost-cutting technologies – regardless of review tool choice.
In addition to proprietary nearline technology in Relativity, Kroll Ontrack offers:
Certified Relativity Expertise: Kroll Ontrack’s experienced global Relativity team includes Relativity Experts, a Relativity Master, Relativity Certified Administrators, Relativity Infrastructure Specialists and Relativity Analytics Specialists. Kroll Ontrack professionals leverage the most advanced Relativity features to skilfully guide matters and recommend strategies to promote the best possible outcome.
Early Case Assessment (ECA) workflow: By allowing only text and metadata to be loaded into the Relativity platform, costs can be significantly reduced. The power and flexibility of Relativity’s search and analytics functionality can be used during ECA to gain early data insight and prioritise the most important data for earlier review.
Assisted Redaction: Sensitive information can be protected and the redaction process can be streamlined through an automated approach to identify and redact Personally Identifiable Information (PII), privileged or other pertinent information based on user-defined criteria.
Grancarich concludes: “With unprecedented user-driven control, our offering of Relativity is a powerful tool to help organisations manage the mounting data and costs associated with data analysis and review. By combining nearline technology, a customised ECA workflow and assisted redaction with our full team of certified Relativity experts and consultants, Kroll Ontrack delivers an efficient, accurate and cost-effective review.”
For more information about Relativity from Kroll Ontrack, visit: http://www.ediscovery.com/uk/solutions/relativity/
About Kroll Ontrack LLC
Kroll Ontrack provides technology-driven services and software to help legal, corporate and government entities as well as consumers manage, recover, search, analyse, and produce data efficiently and cost-effectively. In addition to its award-winning suite of software, Kroll Ontrack provides data recovery, data destruction, electronic discovery and document review services. For more information about Kroll Ontrack and its offerings please visit: http://www.ediscovery.com/uk and follow @KrollOntrackUK on Twitter.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Seoul Semiconductor’s SunLike Series LEDs Win Product of the Year Award from Elektronik Magazine23.3.2018 18:28 | Pressemelding
Seoul Semiconductor, a global innovator of LED products and technology, announced on March 23rd that its SunLike Series natural spectrum LED product won the Gold Award at the Elektronik Product of the Year 2018 Awards, hosted by Elektronik (http://www.elektroniknet.de), a leading German electronics publication. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005646/en/ Product of the Year Award from Elektronik Magazine (SunLike) (Photo: Business Wire) As a publication specializing in electrical and electronic components, “Elektronik” is a prestigious magazine with an illustrious history and the largest number of subscribers in Germany. Over the past 20 years, they have conducted annual surveys among their subscribers to find the “most creative and innovative products.” Based on these survey results, Elektronik selects the top product that with the most impact in its corresponding field, and confers the awards accordingl
Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 16:05 | Pressemelding
Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the
Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 12:52 | Pressemelding
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal
CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 12:50 | Pressemelding
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation
Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 12:46 | Pressemelding
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c
Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 12:00 | Pressemelding
Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at www.aitheon.com/news) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005269/en/ Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on